Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International

Wikipedia Affiliate Button

Home > Press > Arrowhead Pharmaceuticals Receives FDA Clearance to Begin Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease

Abstract:
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has received clearance from the U.S. Food and Drug Administration to proceed with an adaptive Phase 2/3 trial with the potential to serve as a pivotal registrational study of ARO-AAT, the company’s second generation subcutaneously administered RNA interference (RNAi) therapeutic being developed as a treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency (AATD).

Arrowhead Pharmaceuticals Receives FDA Clearance to Begin Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease

Pasadena. CA | Posted on April 15th, 2019

Arrowhead intends to initiate the adaptive design, Phase 2/3 study of ARO-AAT in patients with AATD associated liver disease at various sites in the U.S. in the second quarter of 2019, followed by various international sites in Europe, pending regulatory submission and review. The proposed primary objectives are to evaluate safety and pharmacodynamic dose response, and to evaluate efficacy, defined as an improvement in a histologic grading scale of AATD associated liver disease, and no worsening of liver fibrosis based on Ishak score on end of study biopsy. The company plans to provide additional study details following its initiation.

####

About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts .

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400


Investors and Media:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578

www.lifesciadvisors.com

Copyright © Arrowhead Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

A light-activated remote control for cells April 17th, 2019

NEXUS 2019: Global Summit on Energy Materials and Green Nanotechnology April 16th, 2019

New microscopy method provides more details about nanocomposites April 12th, 2019

Oregon scientists drill into white graphene to create artificial atoms: Patterned on a microchip and working in ambient conditions, the atoms could lead to rapid advancements in new quantum-based technology April 12th, 2019

Govt.-Legislation/Regulation/Funding/Policy

A light-activated remote control for cells April 17th, 2019

New microscopy method provides more details about nanocomposites April 12th, 2019

'Nanobodies' from alpacas could help bring CAR T-cell therapy to solid tumors: Unusually small antibodies, targeted to the tumor micro-environment, curb melanoma and colon cancer in mouse models April 11th, 2019

2D borophene gets a closer look: Rice, Northwestern find new ways to image, characterize unique material April 11th, 2019

Nanomedicine

A light-activated remote control for cells April 17th, 2019

Arrowhead Presents Clinical Data on JNJ-3989 (ARO-HBV) at The International Liver Congress™ April 12th, 2019

'Nanobodies' from alpacas could help bring CAR T-cell therapy to solid tumors: Unusually small antibodies, targeted to the tumor micro-environment, curb melanoma and colon cancer in mouse models April 11th, 2019

Magnetic nanoparticles can 'burn' cancer cells: Magnetic hyperthermia is still a highly experimental cancer treatment, but new research shows that the therapy is tunable April 7th, 2019

Discoveries

A light-activated remote control for cells April 17th, 2019

New microscopy method provides more details about nanocomposites April 12th, 2019

Oregon scientists drill into white graphene to create artificial atoms: Patterned on a microchip and working in ambient conditions, the atoms could lead to rapid advancements in new quantum-based technology April 12th, 2019

'Nanobodies' from alpacas could help bring CAR T-cell therapy to solid tumors: Unusually small antibodies, targeted to the tumor micro-environment, curb melanoma and colon cancer in mouse models April 11th, 2019

Announcements

A light-activated remote control for cells April 17th, 2019

NEXUS 2019: Global Summit on Energy Materials and Green Nanotechnology April 16th, 2019

New microscopy method provides more details about nanocomposites April 12th, 2019

Oregon scientists drill into white graphene to create artificial atoms: Patterned on a microchip and working in ambient conditions, the atoms could lead to rapid advancements in new quantum-based technology April 12th, 2019

Nanobiotechnology

A light-activated remote control for cells April 17th, 2019

Arrowhead Presents Clinical Data on JNJ-3989 (ARO-HBV) at The International Liver Congress™ April 12th, 2019

'Nanobodies' from alpacas could help bring CAR T-cell therapy to solid tumors: Unusually small antibodies, targeted to the tumor micro-environment, curb melanoma and colon cancer in mouse models April 11th, 2019

Magnetic nanoparticles can 'burn' cancer cells: Magnetic hyperthermia is still a highly experimental cancer treatment, but new research shows that the therapy is tunable April 7th, 2019

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project